布雷哌唑真实世界证据:痴呆患者6个月死亡率、住院及急诊就诊
本研究基于2014至2023年Medicare索赔数据,纳入41,871名痴呆患者,比较新使用布雷哌唑与阿立哌唑者的6个月结局。逻辑回归匹配样本显示布雷哌唑组6个月死亡率更低(OR 0.49,95%CI 0.37-0.65),急诊就诊和住院无统计学差异;两阶段最小二乘法校正后各结局均无显著差异。结论认为布雷哌唑与阿立哌唑相比不增加痴呆患者6个月死亡风险。
要点
- 布雷哌唑组6个月死亡率低于阿立哌唑组(OR 0.49,95%CI 0.37-0.65)。
- 两组6个月内急诊就诊和住院无统计学差异。
- 两阶段最小二乘法校正后,死亡、急诊、住院均无显著差异。
核心结论
- 在痴呆患者中,布雷哌唑使用与阿立哌唑使用相比未显示不同的死亡风险。
- 布雷哌唑为痴呆患者提供了重要的治疗选择,考虑到抗精神病药效应的异质性。
研究设计与样本
- 使用2014至2023年Medicare索赔数据Parts A、B、D的100%样本。
- 纳入确诊痴呆、连续参保至少2年、当年新使用布雷哌唑或阿立哌唑的受益人。
- 采用匹配和逻辑回归估计布雷哌唑相比阿立哌唑与新发使用后6个月内死亡、急诊就诊和住院的关系。
- 样本共41,871名痴呆受益人。
主要发现
- 布雷哌唑使用者中71.7%为女性,平均年龄75.7岁;阿立哌唑使用者中69.7%为女性,平均年龄78.0岁。
- 基于逻辑回归和匹配样本,布雷哌唑新使用者6个月死亡率统计学上更低(OR 0.49,95%CI 0.37-0.65)。
- 布雷哌唑与阿立哌唑新使用后6个月内急诊就诊或住院无统计学差异。
- 使用两阶段最小二乘法调整潜在未观测混杂后,两组6个月死亡率、急诊就诊或住院均无统计学显著差异。
临床怎么用
- 对于痴呆患者,布雷哌唑可作为与阿立哌唑相比不增加6个月死亡风险的抗精神病药选择。
- 临床决策中可考虑布雷哌唑用于痴呆患者,但需结合个体情况。
局限性
- 两阶段最小二乘法虽用于消除两组间观测和未观测差异导致的估计偏倚,但样本量小是局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Alzheimer disease and other dementias are accompanied by depression and agitation and other behavioral and neuropsychiatric symptoms. In 2023, brexpiprazole became the first antipsychotic approved by the US Food and Drug Administration to treat agitation in persons with Alzheimer disease, but, like all atypical antipsychotics, it includes a black box warning of an increased risk of mortality among persons with dementia. This study provides real-world evidence of mortality in a heterogeneous sample of brexpiprazole users to understand effects in the population. METHODS: We used a 100% sample of Medicare claims data Parts A, B, and D from 2014 to 2023. Our sample was limited to beneficiaries with diagnosed dementia, who were continuously enrolled for at least 2 years and were new users of the atypical antipsychotics brexpiprazole or aripiprazole in a given year. We used matching and logistic regression to estimate the relationship between incident use of brexpiprazole, compared with aripiprazole, and mortality, emergency department (ED) visits, and hospitalization within 6 months. RESULTS: Among the 41,871 beneficiaries with dementia, 71.7% of brexpiprazole and 69.7% of aripiprazole users were women with a mean age of 75.7 and 78.0 years, respectively. Among persons living with dementia (PLWD), 6-month mortality was statistically lower among new users of brexpiprazole based on estimates from logistic regression and a matched sample of new users of brexpiprazole or aripiprazole (OR 0.49, [95% CI 0.37-0.65]).There was no statistical difference between the incident use of brexpiprazole and aripiprazole use for ED visits or hospitalization within 6 months of use initiation. Adjustment for potential unobserved confounding used two-stage least squares estimation and found no statistically significant differences in six-month mortality, ED visits, or hospitalizations between the 2 groups. DISCUSSION: Brexpiprazole use is not associated with differential mortality risk compared with aripiprazole use among PLWD. Brexpiprazole offers a treatment option which is important given the heterogeneity of effects of antipsychotics on persons. A two-stage least squares method is used to eliminate bias on estimates because of observed and unobserved differences between the 2 groups, but the small sample size is a limitation. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that brexpiprazole does not increase the risk of mortality at 6 months compared with aripiprazole in PLWD.
引用
- Zissimopoulos J, Thunell J, Jacobson M, et al. Real-World Evidence of Brexpiprazole Use and 6-Month Mortality, Hospitalization, and Emergency Department Visits Among Persons With Dementia. Neurology. 2025. PMID: 40609065. doi:10.1212/WNL.0000000000213717
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。